Acute Myeloid Leukemia (non-APL) · line 1 · 7+3 Induction (cytarabine + daunorubicin/idarubicin) ± midostaurin
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-AML-7-3 |
| ID | IND-AML-PEDIATRIC-AAML1031 |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-AML |
| Sources | SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Special-population indication for pediatric AML (≤18). time_critical=true: pediatric AML emergency presentations (hyperleukocytosis, TLS, DIC) require immediate pediatric oncology referral. Missing entity flag: dedicated REG-AAML1031-PEDIATRIC + DRUG-GEMTUZUMAB-OZOGAMICIN — author in PROD-2.
Used By
No reverse references found in the YAML corpus.